retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Effects of retatrutide on body

However, semaglutide has cardiovascular outcome data (the SELECT trial) that tirzepatide does not yet have from a completed dedicated outcomes trial

Wegovy (semaglutide injection) Product Monograph

No need to step through the lower doses again.It's a straightforward switch and for many, probably a welcome one.The MHRA's approval marks the first time a GLP-1 tablet of this kind has been cleared for use in the UK, and it signals a broader shift in how weight management treatment might look in the years ahead

Injectables can over-plump or distort facial contours if not done carefully, and surgical options are invasive and irreversible